Showing 1981-1990 of 3042 results for "".
- A New, Proactive Approach to Newborn Skincarehttps://practicaldermatology.com/news/new-proactive-approach-newborn-skincare/2463138/Aveeno Baby announced the launch of Healthy Start, a proactive approach to newborn skincare featuring a wash and balm duo that are safe to use on newborn skin from birth. Aveeno Baby Healthy Start Newborn Wash is a nourishing cleanser made with prebiotic oat, oat extract, and glycerin to
- Reflections on the “Clearly Me” Psoriasis Exhibithttps://practicaldermatology.com/news/reflecting-on-clearly-me-psoriasis-exhibit-a-qa-with-lindsay-adler/2463137/The “Clearly Me” exhibit in New York, New York, held from May 16-18, showcased real psoriatic patients through dynamic photographic portraits, captured by photographer L
- TODAY Show Feature Criticizes FDA on Sunscreenshttps://practicaldermatology.com/news/today-show-feature-criticizes-fda-sunscreens/2463127/The US Food and Drug Administration (FDA) is doing Americans a disservice by not approving many of the modern sunscreens that are commonly used in Europe, a representative from the Environmental Working Group (EWG) told the TODAY television show last week. “Currently, the US sunscreen mar
- Dr. Jeanine Downie Discusses Fake Botox in TV Segmenthttps://practicaldermatology.com/news/dr-jeanine-downie-discusses-fake-botox-tv-segment/2463070/If public awareness is the key to combatting the counterfeit Botox problem that has been popping up around the country recently, then Jeanine B. Downie, MD, FAAD, took a big step May 13. Dr. Downie, an Editorial Board member for Practical Dermatology's sister publication Mode
- Fish Residues Could Supply Collagenhttps://practicaldermatology.com/news/fish-residues-could-supply-collagen/2462980/Researchers in Norway believe fish residues can supplement current sources of raw materials for collagen and gelatin, according to a Phys.org article. A project called SUPREME, headed by the Norwegian science institute SINTEF Ocean in collaboration with Norwegian university NTNU and the T
- FDA Accepts sNDA for Dermavant's Tapinarof Cream, 1%https://practicaldermatology.com/news/tapinarof-1-cream-progresses-toward-approval-pediatric-eczema/2462895/The U.S. Food and Drug Administration (FDA) has accepted Dermavant's Supplemental New Drug Application (sNDA) for tapinarof cream, 1% (VTAMA®), for the treatment of atopic dermatitis in (AD), according to a news release from the manufacturer. The FDA assigned a Prescription Drug User Fee
- Survey: More than Half of Americans Seek Skin Care and Other Products Aligned with Sustainable Lifestyleshttps://practicaldermatology.com/news/survey-more-half-americans-seek-skin-care-and-other-products-aligned-sustainable-lifestyles/2462882/A recent consumer sentiment survey showed that over half of Americans are inclined to try new products (including those for skin care) marketed as aligned with healthier and more sustainable lifestyles. The survey
- La Roche-Posay Unveils New Serum to Combat Dark Spotshttps://practicaldermatology.com/news/la-roche-posay-unveils-new-serum-combat-dark-spots/2462880/La Roche-Posay has announced the launch of its Mela B3 Dark Spot Serum & Mela B3 UV Daily Moisturizer SPF 30 products. Powered by Melasyl™, the manufacturer said in a news release, L'Oreal's multi-patented ingredient derived from 18 years of research, represents "a breakthrough in pig
- EPI Health Issues Voluntary Recall of Several Products Following Bankruptcyhttps://practicaldermatology.com/news/epi-health-issues-voluntary-recall-several-products-following-bankruptcy/2462869/EPI Health (Novan) is initiating a voluntary recall of various within-expiry human drug products as a result of the closures and discontinuation of the post-marketing quality, regulatory and pharmacovigilance activities for these marketed products. The moves comes after EPI filed Chapter 7 bankru
- UCB Receives European Approval for Hidradenitis Suppurativa Treatment Bimzelxhttps://practicaldermatology.com/news/ucb-receives-european-approval-hidradenitis-suppurativa-treatment-bimzelx/2462815/The European Commission has granted marketing authorization for UCB’s Bimzelx (bimekizumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults with an inadequate response to conventional systemic HS therapy.1 Bimzelx is the first IL-17A and IL-17F bi